Latest Adherium (ASX:ADR) News

Adherium has tapped its major shareholder, Trudell Medical, for a further AUD 1 million unsecured loan to bolster working capital, adding to a recent USD 1.65 million facility.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Adherium Limited has obtained a USD 1.65 million short-term unsecured loan from its major shareholder, Trudell Medical, to fund immediate working capital needs while pursuing capital structure adjustments.

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.

Adherium Limited secured shareholder approval for all resolutions at its June 19, 2026 Extraordinary General Meeting, including a pivotal 1-for-100 share consolidation and approvals tied to recent capital raises and director participation.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Adherium Limited plans a 1-for-100 share consolidation pending shareholder approval, aiming to reduce share count and enhance marketability.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Adherium Limited reports a strong uptick in Remote Patient Monitoring revenue and device activations, driven by new reimbursement codes and strategic partnerships, aiming for 10,000 RPM patients by year-end.